Day 1 - Wednesday, 22 May
Meeting category
Date(s)
22 May 2019 - 24 May 2019
Location
Rome,
Italy
Organizer
European Meeting on HIV & Hepatitis 2019
Related Enduring Materials
Enduring Materials
Downloads:
Program
Opening session -
Chairs
09:00 CEST
Tribute to Andrea De Luca and Ricardo Camacho
09:15 CEST
Andrea De Luca Lecture: The top 10 important observations of the last year affecting clinical management
09:45 CEST
Resistance to integrase inhibitors
Session 1: The role of the reservoir on clinical decision making -
Chairs
Rolf Kaiser, PhD
University of Cologne, Germany
10:45 CEST
How to measure the reservoir
María José Buzón, PhD
Vall d'Hebron Research Institute, Spain
11.15 CEST
How does the reservoir influence the clinician's decisions
Special Session: Genetic Barrier – Role in HIV Treatment Decision -
Chair
12:00 CEST
Genetic Barrier, Basic Principles
12:20 CEST
Genetic Barrier and Reduced Drug Regimens
Romina Quercia, MD, PhD
ViiV Healthcare, United Kingdom
12:40 CEST
Genetic Barrier – Clinical Cases
Session 2: Role of STI management in HIV prevention -
Chairs
David van de Vijver
-
14.20 CEST
Interplay between PrEP and STI
Cécile Bébéar, MD, PhD
University of Bordeaux, France
Abstract - driven presentations - 14.35
14.35 CEST
First results after 52 weeks of informal PrEP use in a cohort of MSM in Southern Spain.
14:50 CEST
European surveillance of HIV drug resistance to NRTI, NNRTI and INSTI in newly diagnosed individuals using next-generation sequencing.
15:15 CEST
Molecular analysis suggests post-migration HIV-1 acquisition among migrants in Paris, France.
15:30 CEST
Trends of transmitted and acquired hiv-1 drug resistance in patients followed in portuguese hospitals between 2001 and 2017
Marta Pingarilho
Portugal
Session 3: Clinical management of HIV - related abstracts -
Chairs
Anne-Mieke Vandamme
-
16:40 CEST
Remembering Ricardo Camacho: HIV-2 Diagnostics, therapy and resistance testing
Rolf Kaiser, PhD
University of Cologne, Germany
16:55 CEST
Seminal HIV-1 RNA and drug concentrations in DTG+3TC dual therapy (ANRS167 Lamidol)
17:10 CEST
Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study
17:25 CEST
High prevalence of the integrase resistance associated accessory mutation L74I in the Russian Federation
17:40 CEST
Fostemsavir (FTR) Week 48 efficacy and evaluation of treatment emergent substitutions in the BRIGHTE study
Max Lataillade
USA
17:55 CEST
Epidemiological study of Doravirine associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy
Day 2 - Thursday, 23 May
Session 4: What's in the pipeline? -
Chairs
08.30 CEST
Presentations from scientists from the industry
Harmony P. Garges, MD, MPH
Vice President and Head, Global Medical Affairs, ViiV Healthcare, USA
Luisa Stamm, MD, PhD
Executive Director, HIV and Emerging Viral Infections, Gilead Sciences, USA
Hanneke Schuitemaker, PhD
Vice President, Head Viral Vaccine Discovery and Translational Medicine, Janssen, The Netherlands
Special Session: Clinical considerations in choosing first-line therapy -
Chair
11:15 CEST
Welcome and introduction
Carlo Federico Perno, MD, PhD
University of Milan, Italy
11:20 CEST
Same day treatment initiation
11:40 CEST
First line therapies: implications for long term resistance
Session 5: Management of viral hepatitis I -
Chairs
Carlo Perno
-
13:15 CEST
Novel compounds for HBV therapy
14:15 CEST
Abstract-driven presentations
The integration of Hepatitis B virus in relevant regions of human genome is a common event in the setting of HBeAg negative chronic infection despite limited liver disease: implications for an altered cell metabolism
Romina Salpini, Italy
The transmission dynamics of acute HCV infections in HIV-positive men who have sex with men in the Netherlands is suitable for targeted risk reduction strategies
Stephanie Popping, the Netherlands
Session 6: Management of viral hepatitis II - 15.45
15.45 CEST
Clinical relevance of HCV rare subtypes
16:15 CEST
Abstract-driven presentations
Clinical and virological characteristics of patients with chronic hepatitis C and failure to a Glecaprevir and Pibrentasvir (G/P) treatment in real world
Federico Garcia, Spain
Retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen after performing a genotypic resistance test: the Italian Vironet C real life experience
Velia Chiara Di Maio
Specific NS5A polymorphisms correlate with hepatocellular carcinoma in cirrhotic patients infected with HCV genotype 1b
Mohammad Altkhatib
Day 3 - Friday, 24 May
Session 7: Clinical management challenges - 08:30
08:30 CEST
The new patient - with what & when
09:30 CEST
The pregnant woman - update
Session 10: Progress in cure / elimination approaches -
Chair
Carlo Perno
-
11:45 CEST
Update on HIV cure research
Linos Vandekerckhove, MD, PhD
University of Gent, Belgium
12:15 CEST
Hepatitis C elimination research
12:45 CEST
Perspectives in HBV cure research
13:30 CEST
Ricardo Camacho Award ceremony and closure of the meeting
Overview
Welcome
Over 300 participants from all over the world attended the 17th edition of the European Meeting on HIV & Hepatitis that took place on 22-24 May 2019 at the Roma Eventi - Fontana di Trevi Conference Centre in Rome, Italy. The Organizing Committee would like to thank all the invited speakers and participants for their contribution to this meeting!
We are grateful to our supporters ViiV Healthcare, Gilead Sciences and Janssen for making this event possible.
We would also like to congratulate the RICARDO CAMACHO AWARD winners:
Roberta Gagliardini, Lazzaro Spallanzani National Institute For Infectious Diseases Irccs, Rome, Italy for Poster presentation entitled "Impact of resistance mutations on virological efficacy of DTG-based maintenance two-drug regimens: a cohort study".
Laura Hebberecht, AIDS Reference Laboratory Ugent, Gent, Belgium, for Oral abstract presentation entitled "Single genome sequencing of near full-length HIV-1 RNA".
General Information
Meeting Objectives
This meeting aims to:
- Gather professionals in the fields of HIV and hepatitis clinical care and research in an interactive workshop setting
- Provide a platform for presentation and discussion of the latest developments in the field of antiviral
drug development
- Map important current studies and results
- Translate new data into treatment guidelines
- Educate clinicians on how to best implement current and new drugs in clinical practice
- Gather professionals in the fields of HIV and hepatitis clinical care and research in an interactive workshop setting
- Provide a platform for presentation and discussion of the latest developments in the field of antiviral
drug development
- Map important current studies and results
- Translate new data into treatment guidelines
- Educate clinicians on how to best implement current and new drugs in clinical practice
Learning Objectives
After participating in this activity, participants will be able to:
- Summarize recent results in drug development (including most recent clinical trial results) for HIV, HBV and HCV
- Integrate the latest scientific results into daily clinical care to improve the quality of life of hepatitis/
HIV-positive individuals
- Recognize the future challenges in screening, monitoring, and diagnosis of HIV/HBV- or HCV-positive patients and develop new concepts for research and care strategies
- Summarize recent results in drug development (including most recent clinical trial results) for HIV, HBV and HCV
- Integrate the latest scientific results into daily clinical care to improve the quality of life of hepatitis/
HIV-positive individuals
- Recognize the future challenges in screening, monitoring, and diagnosis of HIV/HBV- or HCV-positive patients and develop new concepts for research and care strategies
Committees
The members of the Program Committee assist the Organizing Committee by providing them with suggestions for the scientific program. In addition, they participate in reviewing abstracts and play an active role during the workshop as moderators and/or chairs of sessions.
The members of the Organizing Committee are a group of carefully selected experts and inspirational leaders in their respective fields. They meet frequently to discuss the scientific program of the workshop, identify interesting topics and candidate speakers, and review all submitted abstracts.
Scientific Committee
The members of Scientific Committee are hand-picked by the Organizing Committee and the conference secretariat based on their significant contributions and commitment to the field. They assist the Organizing Committee by providing them with suggestions for speakers and topics. In addition, members of the Scientific Committee participate in reviewing submitted abstracts, and play an active role during the workshop as moderators and/or chairs of sessions.
- Carlos Beltran, MD - Chilean AIDS Group, Chile
- Marina Bobkova, PhD - Ivanovsky Institute of Virology, Russia
- Rolf Kaiser, PhD - University of Cologne, Germany
- Leon Kostrikis, PhD - University of Cyprus, Cyprus
- Clive Loveday, PhD - ICVC Charitable Trust, Clinical Virology, UK
- Monique Nijhuis, PhD - University Medical Centre Utrecht, the Netherlands
- Mario Poljak, MD, PhD - Institute for Microbiology and Immunology, Slovenia
- Gary Rubin, MD - University of Toronto, Canada
- Anders Sönnerborg, MD, PhD - Karolinska Institut, Sweden
- Jan Albert, MD - Karolinska Institute, Sweden
- Janusz Stanczak, PhD - University of Warsaw, Poland
- David van de Vijver, PharmD PhD - Erasmus University Rotterdam, the Netherlands
- Hauke Walter, MD - Medizinisches Labor Stendhal, Germany
- Maurizio Zazzi, PhD - University of Siena, Italy
- Milosz Parczewski, MD, PhD - Pomeranian Medical University, Poland
- Maria Santoro, MD - University of Rome "Tor Vergata", Italy
Support
Support
Language
Related Programs
